

OPEXA THERAPEUTICS, INC.

FORM 8-K (Current report filing)

Filed 12/01/04 for the Period Ending 11/24/04

Address	2635 TECHNOLOGY FOREST BLVD. THE WOODLANDS, TX 77381
Telephone	(281) 272-9331
CIK	0001069308
Symbol	OPXA
SIC Code	2834 - Pharmaceutical Preparations
Fiscal Year	12/31

UNITED STATES
SECURITIES EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 24, 2004

PHARMAFRONTIERS CORP.

(Exact name of registrant as specified in its charter)

Texas	000-25513	760333165
-----	-----	-----
State of organization)	(Commission File Number)	(IRS Employer Identification No.)
835 Greens Parkway		
Suite 150		
Houston, Texas		77067
-----	-----	-----
(Address of principal executive offices)		(Zip Code)

Registrant's Telephone Number, including area code: (281) 272-9331

Former name or former address, if changed since last report: Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 5.02. DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.

On November 24, 2004, PharmaFrontiers Corp. (the "Company") announced the resignation of Dwayne Deslatte as a member of the Board of Directors ("Board") for personal reasons, effective immediately. Mr. Deslatte served on the Board since March 2004 and was not a member of any board committees. Mr. Deslatte had no disputes or differences in opinion on any matter relating to the Company's operations, policies or practices.

On November 24, 2004, Paul Frison was appointed to the Board to fill the vacancy created by Mr. Deslatte's resignation. As of the date of the filing of this report, it has not been determined which committee(s), if any, he will serve.

Mr. Frison has not been involved with a related transaction or relationship as defined by Item 404(a) of Regulation S-B between the Company and him. Additionally, there is no arrangement or understanding between Mr. Frison and any other person pursuant to which Mr. Frison was selected as a director.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBIT

(c) Exhibits

The following exhibits are to be filed as part of this 8-K:

EXHIBIT NO. -----	IDENTIFICATION OF EXHIBIT -----
99.1	Press release dated December 1, 2004

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PHARMAFRONTIERS CORP.

By: /s/ David McWilliams

David McWilliams, Chief Executive Officer

DATE: December 1, 2004

EXHIBIT INDEX

Exhibit No. -----	Description -----
99.1	Press Release dated December 1, 2004

For Immediate Release For further information contact:

Tom Sommers
(713) 222-1600

PHARMAFRONTIERS NAMES HTC HEAD PAUL FRISON TO BOARD

HOUSTON, December 1, 2004 - Cell therapy developer PharmaFrontiers Corporation (OTCBB:PFTR.OB) has elected Paul M. Frison, president and CEO of the Houston Technology Center (HTC), to the company's Board of Directors.

"Paul's deep experience with technology-driven growth companies will add a valuable perspective as we approach the dynamic opportunities presented by our adult stem cell tissue regeneration technology," said PharmaFrontiers CEO David McWilliams.

Before helping to found the HTC in 1999, Frison spent 24 years as President and/or CEO building and leading three Houston-based public companies, NYSE-listed LifeMark, NASDAQ-listed ComputerCraft, and LifeCell Corp. (LIFC:NASDAQ-NM). He has served on the boards of four other start-up companies, been involved in numerous mergers and acquisitions, and raised multiple rounds of venture capital, two IPOs and more than a dozen follow-on rounds of public market financings.

Frison currently serves on the Board of Directors of the HTC, Micromed Technologies, The Institute of Research and Rehabilitation (TIRR), The Entrepreneurship Institute, The Houston Entrepreneurs Foundation, The Lions Eye Foundation - Houston, Boy Scouts of America - Houston, Texas Council of AEA, Texchange, and the Advisory Council of the University of Houston - College of Technology. He was the Houston 2004 Ernst & Young Entrepreneur of the Year for Supporter of Entrepreneurship and is one of the 3 national finalists for Supporter of Entrepreneurship awarded by the Kauffman Foundation, Microsoft and Ernst & Young. He received his B.A. from Occidental College in Los Angeles, California.

With Frison's election, the number of PharmaFrontiers board members remains at six as a result of the resignation of Dwayne Deslatte as a director.

PharmaFrontiers' strategy is to develop and commercialize cell therapies to treat several major disease areas such as cardiac and pancreatic conditions and multiple sclerosis (MS). The company holds the exclusive worldwide license from the U.S. Department of Energy's Argonne National Laboratory for the use of adult pluripotent stem cells derived from patients' own circulating blood. It also owns patented and proprietary individualized cell therapies that are in FDA Phase I/II human dose ranging clinical trials to evaluate their safety and effectiveness in treating MS.

This press release contains forward-looking statements about PharmaFrontiers within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. For example, statements in the future tense, words such as "anticipates", "estimates", "expects", "intends", "plans", "believes", and words and terms of similar substance used in connection with any discussion of future results, performance or achievements identify such forward-looking statements. Those forward-looking statements involve risks and uncertainties and are not guarantees of future results, performance or achievements, and actual results, performance or achievements could differ materially from the Company's current expectations as a result of numerous factors, including those risks more fully disclosed in the Company's filings with the U.S. Securities and Exchange Commission, including the Company's Report on Form 8-K dated June 4, 2004. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.

#

KEYWORDS: Health & Medical, Finance, Stem Cells, Houston, Texas COMPANIES: PharmaFrontiers Corporation (OTCBB:PFTR.OB)